Jerry, Michelle Arcona, Steve McMorrow, Donna Schwartz, Hana Princic, Nicole Sasane, Rahul
Published in
ClinicoEconomics and outcomes research : CEOR
To examine work loss and indirect costs during the three-year periods prior to and following initial diagnosis of Parkinson's disease (PD) in patients and in spouses of PD patients, as well as direct costs of healthcare. This is a retrospective, observational cohort study using the MarketScan Commercial and Health and Productivity Management databa...
Ramjee, Lauren Vurgun, Nesrin Ngai, Christopher Patel, Mit Tremblay, Gabriel
Published in
ClinicoEconomics and outcomes research : CEOR
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A nephropathy (IgAN) from a United States (US) societal perspective. A lifetime horizon, semi-Markov model was developed that consisted of nine health states: ...
Punch, Donna Davis, Jonathan S Hahn, Rebecca Gill, Rav Hsiao, Chia-Wen Kara, Richard
Published in
ClinicoEconomics and outcomes research : CEOR
Surgical procedure packs are commonly used in ophthalmological surgeries, but quantitative evidence demonstrating the time efficiency and economic impact of their use is limited. Evaluating the time and cost of surgical pack use is particularly important for publicly funded healthcare systems with tight budgets and/or an emphasis on value-based car...
Nyholm, Nanna Danø, Anne Schnack, Henrik Colombo, Giorgio Lorenzo
Published in
ClinicoEconomics and outcomes research : CEOR
The objective of this study was to optimise the cost-effectiveness of different anti-IL17 treatment sequences used in the treatment of moderate-to-severe plaque psoriasis in Italy and Germany over a five-year time horizon. We adjusted a previously published treatment sequence model for biologic drugs used in psoriasis treatment to an Italian and Ge...
Sunariyanti, Endang Andayani, Tri Murti Endarti, Dwi Puspandari, Diah Ayu
Published in
ClinicoEconomics and outcomes research : CEOR
The cost of treating chronic kidney disease requires large funds. Chronic kidney disease financing ranks 2nd in BPJS as the highest financing. All cost components in the treatment of chronic kidney disease are considered high, so adjustments and efficiency are needed. This study aims to perform a cost analysis in chronic kidney patients. In this ar...
Haji-Sheikhi, Farnoosh Fragala, Maren S Bare, Lance A Rowland, Charles M Goldberg, Steven E
Published in
ClinicoEconomics and outcomes research : CEOR
Strategies to mitigate rising health-care costs are a priority for patients, employers, and health insurers. Yet gaps currently exist in whether health risk assessment can forecast medical claims costs. This study examined the ability of a health quotient (HQ) based on modifiable risk factors, age, sex, and chronic conditions to predict future medi...
Agiro, Abiy Dwyer, Jamie P Oluwatosin, Yemisi Desai, Pooja
Published in
ClinicoEconomics and outcomes research : CEOR
Hyperkalemia, defined as abnormally high serum potassium levels of ≥5.1 mmol/L, is associated with increased medical costs. This real-world study evaluated the impact of long-term sodium zirconium cyclosilicate (SZC) therapy on medical costs in patients with hyperkalemia. This retrospective, comparative study used claims data from IQVIA PharMetrics...
Kalinić, Dragan Škrbić, Ranko Vulić, Duško Stoisavljević-Šatara, Svjetlana Stojaković, Nataša Stojiljković, Miloš P Marković-Peković, Vanda Golić Jelić, Ana Pilipović-Broćeta, Nataša Divac, Nevena
...
Published in
ClinicoEconomics and outcomes research : CEOR
In last two decades, there have been substantial changes in the pattern of lipid-modifying medicines utilisation following the new treatment guidelines based on clinical trials. The main purpose of this study was to analyse the overall utilisation and expenditure of lipid-modifying medicines in the Republic of Srpska, Bosnia and Herzegovina during ...
Gertz, Morie Abonour, Rafat Gibbs, Sarah N Finkel, Muriel Landau, Heather Lentzsch, Suzanne Lin, Grace Mahindra, Anuj Quock, Tiffany Rosenbaum, Cara
...
Published in
ClinicoEconomics and outcomes research : CEOR
Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among...
Arhin, Kwadwo Frimpong, Albert Opoku Acheampong, Kwame
Published in
ClinicoEconomics and outcomes research : CEOR
Investment in primary health care (PHC) to achieve universal health coverage (UHC) and better health outcomes remains a key global health agenda. This study aimed to assess the effects of PHC spending on UHC and health outcomes. The study used the Grossman Health Production Model and conducted econometric analyses using panel data from 2016 to 2019...
